Ameritas Advisory Services’s Clearside Biomedical CLSD Stock Holding History

Ameritas Advisory Services’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,775	Closed	-$46.6K	–	2720
2022 Q4	$46.6K	Buy	2,775 +1,388	+100%	+$25K	﹤0.01%	864
2022 Q3	$24K	Hold	1,387	–	–	﹤0.01%	754
2022 Q2	$31K	Hold	1,387	–	–	﹤0.01%	787
2022 Q1	$48K	Hold	1,387	–	–	﹤0.01%	822
2021 Q4	$57K	Buy	+1,387	New	+$89.8K	﹤0.01%	802

Other funds holding CLSD

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Ameritas Advisory Services's CLSD Position: Q1 2023 in Review

Ameritas Advisory Services sold out of Clearside Biomedical (CLSD) in Q1 2023, closing a stake of 2,775 shares — an estimated $46.6K sold.

Ameritas Advisory Services first reported a position in CLSD in Q4 2021 and held it in 5 quarters. The position peaked at $57K in Q4 2021. 50 funds tracked by Wall St. Rank hold CLSD as of Q1 2023.

Ameritas Advisory Services reported no remaining Clearside Biomedical position as of Q1 2023 after selling out during the quarter.
Ameritas Advisory Services sold 2,775 Clearside Biomedical shares in Q1 2023, an estimated $46.6K.
Ameritas Advisory Services first reported a position in Clearside Biomedical in Q4 2021 and held it in 5 quarters.
Ameritas Advisory Services's Clearside Biomedical position peaked at $57K in Q4 2021.
50 funds tracked by Wall St. Rank held Clearside Biomedical as of Q1 2023.

Based on Ameritas Advisory Services's 13F filing for Q1 2023, filed 28 Apr 2023.